VRAX
Virax Biolabs Group Ltd
$
0.784
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.810
Open
0.810
VWAP
0.79
Vol
23.57K
Mkt Cap
3.40M
Low
0.7755
Amount
18.61K
EV/EBITDA(TTM)
--
Total Shares
2.36M
EV
-655.33K
EV/OCF(TTM)
--
P/S(TTM)
465.60
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
Show More
Valuation Metrics
The current forward P/E ratio for Virax Biolabs Group Ltd (VRAX.O) is -0.78, compared to its 5-year average forward P/E of -3.52. For a more detailed relative valuation and DCF analysis to assess Virax Biolabs Group Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.52
Current PE
-0.78
Overvalued PE
1.82
Undervalued PE
-8.86
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.44
Current EV/EBITDA
-0.78
Overvalued EV/EBITDA
4.62
Undervalued EV/EBITDA
-7.50
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
44.55
Current PS
84.35
Overvalued PS
168.00
Undervalued PS
-78.89
Financials
Annual
Quarterly
FY2022Q4
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2022Q4
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
VRAX News & Events
Events Timeline
2025-07-18 (ET)
2025-07-18
22:22:29
Virax Biolabs receives noncompliance notice from Nasdaq
2025-03-18 (ET)
2025-03-18
07:32:36
Virax Biolabs enrolls first patients in T-cell dysfunction study
2024-12-10 (ET)
2024-12-10
06:31:33
Virax Biolabs enters non-exclusive distribution agreement with Tebubio
Sign Up For More Events
Sign Up For More Events
News
7.0
08-05CNBCHow an obscure SEC proposal could boost listings on European stock exchanges
7.0
07-18NewsfilterVirax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
4.0
03-31BenzingaVirax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating
Sign Up For More News
People Also Watch
FAQ
What is Virax Biolabs Group Ltd (VRAX) stock price today?
The current price of VRAX is 0.7839 USD — it has decreased -0.76 % in the last trading day.
What is Virax Biolabs Group Ltd (VRAX)'s business?
What is the price predicton of VRAX Stock?
What is Virax Biolabs Group Ltd (VRAX)'s revenue for the last quarter?
What is Virax Biolabs Group Ltd (VRAX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Virax Biolabs Group Ltd (VRAX)'s fundamentals?
How many employees does Virax Biolabs Group Ltd (VRAX). have?